FIXED-DOSE HEPARIN EFFECTIVE IN VTE TREATMENT
A recent study of 708 patients proved that fixed-dose subcutaneous unfractionated heparin (UFH) was as safe and effective as low-molecular-weight heparin (LMWH) in patients with acute venous thromboembolism (VTE) in the outpatient setting. Patients received either an initial dose of 333 units/kg UFH, followed by 250 units/kg every 12 hours, or 100 IU/kg LMWH (enoxaparin or dalteparin) every 12 hours. The percentage of patients with recurrent VTE was similar in both groups, as were rates of major bleeding, within the first 10 days of treatment. Treatment was administered entirely on an outpatient basis for the majority of patients.
LMWH is commonly used in outpatients to treat acute, uncomplicated episodes of VTE. LMWH is expensive, however, and many patients cannot afford the cost of the drug. The results of this study indicate that UFH may offer a less expensive alternative for treatment. Additional studies are needed to verify these results and further define the role of UFH in outpatient management of VTE.
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
Articles in this issue
almost 19 years ago
Article
Aggressive Management of Type 2 Diabetes to Prevent Macrovascular ComplicationsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
Evaluation of Pharmacist-Driven Penicillin Allergy ReconciliationSeptember 17th 2025
Pharmacists Can Apply Their Expertise to the Medical Psilocybin ActSeptember 16th 2025
From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy ResearchSeptember 15th 2025
